Department of Urology, Changzhou No. 2 People's Hospital Affiliated to Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, Jiangsu Province, China.
Gene. 2013 Feb 15;515(1):56-61. doi: 10.1016/j.gene.2012.11.035. Epub 2012 Dec 11.
BACKGROUND/AIMS: Interleukin-13 (IL13) is an immunoregulatory cytokine which plays an important role in carcinogenesis through affecting tumor immunosurveillance. Many studies had reported the influence of IL13 rs1800925 and rs20541 polymorphisms on cancer risk, however, with inconclusive results. The aim of the present study was to conduct a meta-analysis to clarify the relationship.
Twenty studies including a total of 6713 cancer cases and 8693 controls for IL13 rs20541 polymorphism and 4081 cancer cases and 6202 controls for IL13 rs1800925 polymorphism were included in the meta-analysis. Data were extracted from these studies and odds ratios with corresponding 95% confidence intervals were computed to estimate the strength of the association.
Overall, the IL13 rs20541 polymorphism were associated with significantly decreased cancer risk in all genetic models (AA vs. GG: OR=0.82, 95%CI=0.71-0.95; GA vs. GG: OR=0.92, 95%CI=0.85-0.99; GA/AA vs. GG: OR=0.90, 95%CI=0.85-0.97; AA vs. GG/GA: OR=0.85, 95CI%=0.74-0.98). In the stratified analyses, significant effects were found among European populations, studies with population-based controls and studies of glioma. No influence of the IL13 rs1800925 polymorphism on the overall cancer risk was observed. However, in the stratified analyses, we found the IL13 rs1800925 polymorphism was significantly associated with decreased risk for glioma (CT vs. TT: OR=0.72, 95%CI=0.55-0.93; CT/TT vs. TT: OR=0.76, 95%CI=0.62-0.89).
Our meta-analysis suggests that the IL13 rs20541 polymorphism contributes to susceptibility to cancer, especially for glioma; and the IL13 rs1800925 polymorphism may be associated with glioma risk.
背景/目的：白细胞介素-13（IL13）是一种免疫调节细胞因子，通过影响肿瘤免疫监视在致癌作用中发挥重要作用。许多研究报道了 IL13 rs1800925 和 rs20541 多态性对癌症风险的影响，但结果并不一致。本研究的目的是进行荟萃分析以阐明这种关系。
共纳入 20 项研究，包括 IL13 rs20541 多态性的 6713 例癌症病例和 8693 例对照，IL13 rs1800925 多态性的 4081 例癌症病例和 6202 例对照。从这些研究中提取数据，并计算比值比及其相应的 95%置信区间，以评估关联的强度。
总体而言，IL13 rs20541 多态性与所有遗传模型的癌症风险降低显著相关（AA 与 GG：OR=0.82，95%CI=0.71-0.95；GA 与 GG：OR=0.92，95%CI=0.85-0.99；GA/AA 与 GG：OR=0.90，95%CI=0.85-0.97；AA 与 GG/GA：OR=0.85，95%CI=0.74-0.98）。在分层分析中，在欧洲人群、基于人群的对照研究和胶质瘤研究中发现了显著影响。IL13 rs1800925 多态性对总体癌症风险没有影响。然而，在分层分析中，我们发现 IL13 rs1800925 多态性与胶质瘤风险降低显著相关（CT 与 TT：OR=0.72，95%CI=0.55-0.93；CT/TT 与 TT：OR=0.76，95%CI=0.62-0.89）。
本荟萃分析表明，IL13 rs20541 多态性与癌症易感性有关，特别是与胶质瘤有关；IL13 rs1800925 多态性可能与胶质瘤风险有关。
